Cases
Keryx Biopharmaceuticals, Inc. (KERX)
Merger
Overview
Overview
- Date:
- 7/2/2018
- Company Name:
- Keryx Biopharmmaceuticals, Inc.
- Stock Symbol:
- KERX
- Company Name - Buyer:
- Akebia Therapeutics, Inc.
- Status:
- Filed
NEW YORK, July 2, 2018 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Keryx Biopharmaceuticals, Inc. (NYSE: KERX) stockholders concerning the proposed acquisition of the company by Akebia Therapeutics, Inc.
Pursuant to the proposed transaction, which is valued at approximately $1.3 billion, Keryx stockholders will receive 0.37433 in stocks per share of their Keryx common stock. The investigation concerns whether the Keryx Board obtained the best price possible for Keryx stockholders.
If you own Keryx shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.
Pursuant to the proposed transaction, which is valued at approximately $1.3 billion, Keryx stockholders will receive 0.37433 in stocks per share of their Keryx common stock. The investigation concerns whether the Keryx Board obtained the best price possible for Keryx stockholders.
If you own Keryx shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 308-1869, or by filling out the contact form below. There is no cost or obligation to you.